ArticleTissue engineering. Part A2017
Article in Tissue engineering. Part A, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Adipose-derived microvascular fragments: Functional microtissue units driving vascular integration and multidimensional tissue regeneration.Regenerative therapy · 2026Review
- Application and Mechanism of Adipose Tissue-Derived Microvascular Fragments in Tissue Repair and Regeneration.Biomolecules · 2025Review
- Neuromuscular Regeneration of Volumetric Muscle Loss Injury in Response to Agrin-Functionalized Tissue Engineered Muscle Grafts and Rehabilitative Exercise.Advanced healthcare materials · 2025Article
- Review
- Article
- Transcriptome profiling of a synergistic volumetric muscle loss repair strategy.BMC musculoskeletal disorders · 2023Article
- Recent Advances in the Application of Natural and Synthetic Polymer-Based Scaffolds in Musculoskeletal Regeneration.Polymers · 2022Review
- Adipogenic Differentiation Alters Properties of Vascularized Tissue-Engineered Skeletal Muscle.Tissue engineering. Part A · 2022Article
- Cells, scaffolds, and bioactive factors: Engineering strategies for improving regeneration following volumetric muscle loss.Biomaterials · 2021Review
- Translational products of adipose tissue-derived mesenchymal stem cells: Bench to bedside applications.World journal of stem cells · 2021Review
- GLUT4-overexpressing engineered muscle constructs as a therapeutic platform to normalize glycemia in diabetic mice.Science advances · 2021Article
- Old and new biomarkers for volumetric muscle loss.Current opinion in pharmacology · 2021Review
- Self-aligned myofibers in 3D bioprinted extracellular matrix-based construct accelerate skeletal muscle function restoration.Applied physics reviews · 2021Article
- Functionalizing biomaterials to promote neurovascular regeneration following skeletal muscle injury.American journal of physiology. Cell physiology · 2021Review
- Current Strategies for the Regeneration of Skeletal Muscle Tissue.International journal of molecular sciences · 2021Review
- Pre-Clinical Cell Therapeutic Approaches for Repair of Volumetric Muscle Loss.Bioengineering (Basel, Switzerland) · 2020Review
- A Straightforward Approach to Engineer Vascularized Adipose Tissue Using Microvascular Fragments.Tissue engineering. Part A · 2020Article
- Skeletal Muscle Tissue Engineering: Biomaterials-Based Strategies for the Treatment of Volumetric Muscle Loss.Bioengineering (Basel, Switzerland) · 2020Review
- Long-Term Evaluation of Functional Outcomes Following Rat Volumetric Muscle Loss Injury and Repair.Tissue engineering. Part A · 2020Article
- Vascularized and Innervated Skeletal Muscle Tissue Engineering.Advanced healthcare materials · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High velocity impact injuries can often result in loss of large skeletal muscle mass, creating defects devoid of matrix, cells, and vasculature. Functional regeneration within these regions of large volumetric muscle loss (VML) continues to be a significant clinical challenge. Large cell-seeded, space-filling tissue-engineered constructs that may augment regeneration require adequate vascularization to maintain cell viability. However, the long-term effect of improved vascularization and the effect of addition of myoblasts to vascularized constructs have not been determined in large VMLs. Here, our objective was to create a new VML model, consisting of a full-thickness, single muscle defect, in the rat biceps femoris muscle, and evaluate the ability of myoblast-seeded vascularized collagen hydrogel constructs to augment VML regeneration. Adipose-derived microvessels were cultured with or without myoblasts to form vascular networks within collagen constructs. In the animal model, the VML injury was created in the left hind limb, and treated with the harvested autograft itself, constructs with microvessel fragments (MVF) only, constructs with microvessels and myoblasts (MVF+Myoblasts), or left empty. We evaluated the formation of vascular networks in vitro by light microscopy, and the capacity of vascularized constructs to augment early revascularization and muscle regeneration in the VML using perfusion angiography and creatine kinase activity, respectively. Myoblasts (Pax7+) were able to differentiate into myotubes (sarcomeric myosin MF20+) in vitro. The MVF+Myoblast group showed longer and more branched microvascular networks than the MVF group in vitro, but showed similar overall defect site vascular volumes at 2 weeks postimplantation by microcomputed tomography angiography. However, a larger number of small-diameter vessels were observed in the vascularized construct-treated groups. Yet, both vascularized implant groups showed primarily fibrotic tissue with adipose infiltration, poor maintenance of tissue volume within the VML, and little muscle regeneration. These data suggest that while vascularization may play an important supportive role, other factors besides adequate vascularity may determine the fate of regenerating volumetric muscle defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.